Joseph Parisi, MD
Ophthalmology · Seneca, SCNPI 1760451892
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (49.5%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Alcon at 33.0% of the total. Among ophthalmology clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 358 payments — averaging $99.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$12K
- Carl Zeiss Meditec, Inc.$8K
- Bausch & Lomb Americas Inc.$6K
- Biotissue Holdings Inc.$2K
- Carl Zeiss Meditec USA, Inc.$2K
- AbbVie$889
- plus $5K from 23 others
Across 5 payments — averaging $3600.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$18K
What the payments were for
- Consulting fees$12,54035%
- Speaking & faculty fees$3,50010%
- Travel & lodging$1,8335%
- Food & beverage$17,53649%
- Education$180%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 161 | $11,689 |
| Carl Zeiss Meditec, Inc. | 18 | $8,253 |
| Bausch & Lomb Americas Inc. | 6 | $5,748 |
| Biotissue Holdings Inc. | 13 | $2,251 |
| Carl Zeiss Meditec USA, Inc. | 17 | $2,048 |
| AbbVie(2 entities) | 51 | $889 |
| Glaukos Corporation | 9 | $749 |
| Rxsight Inc | 6 | $633 |
| Ivantis, Inc | 8 | $530 |
| Sight Sciences, Inc. | 3 | $323 |
| Ocular Therapeutix, Inc. | 5 | $295 |
| Lensar, Inc. | 1 | $235 |
| Rayner Intraocular Lenses Limited | 6 | $229 |
| Amgen(2 entities) | 5 | $202 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $184 |
| Tearlab Corp | 1 | $174 |
| Quidel Corporation | 5 | $167 |
| Novartis | 10 | $156 |
| Staar Surgical Company | 2 | $135 |
| Oyster Point Pharma, Inc. | 7 | $129 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $108 |
| Merz North America, Inc. | 1 | $82 |
| Omeros Corporation | 2 | $61 |
| Galderma Laboratories, L.p. | 4 | $51 |
| Tarsus Pharmaceuticals, Inc. | 2 | $48 |
| Shire North American Group Inc | 2 | $30 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Harrow Eye, LLC | 1 | $16 |
| Carl Zeiss Meditec Digital Innovations LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERACITY SURGICAL$4,793
- Clareon$3,543
- CALLISTO eye$3,090
- AcrySof IQ PanOptix UV IOL$2,762
- AcrySof IQ VIVITY$2,678
- IOLMaster$2,500
- miLOOP$2,500
- VisuMax$2,143
- CLARUS 500$2,061
- Cataract Suite$1,750
- FORUM$1,750
- ARTEVO 800$1,711
- CT Lucia$1,000
- LenSx$740
- AcrySof$630
- RXSIGHT CONTACT LENS$616
- RXSIGHT INJECTOR CARTRIDGE$616
- RXSIGHT INJECTOR HANDPIECE$616
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$616
- Wavelight Refractive Suite$609
How this compares
$35,446 in reported general payments places this provider in the 95th percentile of 293 ophthalmology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 24 | $13,656 |
| MieboPerfluorohexyloctane/Pf | 12 | $13,419 |
| Cyclosporine | 17 | $8,606 |
| ProlensaBromfenac Sodium | 11 | $3,855 |
| Latanoprost | 169 | $2,077 |
| Prednisolone Acetate | 20 | $645 |
| MoxifloxacinMoxifloxacin Hcl | 20 | $332 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 17 | $295 |
| Timolol Maleate | 23 | $150 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan | $889 | $13,65624 claims |
| Bausch & Lomb Americas Inc.Miebo | $5,748 | $13,41912 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $108 | $3,85511 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 293 ophthalmology providers in South Carolina.
Other ophthalmology in Seneca
- Scott MassiosSeneca$6K
- Kerry SolomonMt Pleasant$1.7M
- William ClarkWest Columbia$768K
- George WaringMt Pleasant$645K
- Karolinne RochaCharleston$552K
- Joseph BishopHilton Head Island$136K
- Erik HappMt Pleasant$124K
- Matthew ClaryColumbia$119K
- Kunal KanitkarLexington$83K
- Carl SloanMyrtle Beach$78K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.